A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

Bibliographic Details
Main Authors:	Rutgeerts, Paul J, Fedorak, Richard N, Hommes, Daan W, Sturm, Andreas, Baumgart, Daniel C, Bressler, Brian, Schreiber, Stefan, Mansfield, John C, Williams, Marna, Tang, Meina, Visich, Jennifer, Wei, Xiaohui, Keir, Mary, Luca, Diana, Danilenko, Dimitri, Egen, Jackson, O'Byrne, Sharon
Format:	Online
Language:	English
Published:	BMJ Group 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711369/

id	pubmed-3711369
recordtype	oai_dc
spelling	pubmed-37113692013-07-16 A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis Rutgeerts, Paul J Fedorak, Richard N Hommes, Daan W Sturm, Andreas Baumgart, Daniel C Bressler, Brian Schreiber, Stefan Mansfield, John C Williams, Marna Tang, Meina Visich, Jennifer Wei, Xiaohui Keir, Mary Luca, Diana Danilenko, Dimitri Egen, Jackson O'Byrne, Sharon Inflammatory Bowel Disease BMJ Group 2013-08 2012-06-20 /pmc/articles/PMC3711369/ /pubmed/22717454 http://dx.doi.org/10.1136/gutjnl-2011-301769 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Rutgeerts, Paul J Fedorak, Richard N Hommes, Daan W Sturm, Andreas Baumgart, Daniel C Bressler, Brian Schreiber, Stefan Mansfield, John C Williams, Marna Tang, Meina Visich, Jennifer Wei, Xiaohui Keir, Mary Luca, Diana Danilenko, Dimitri Egen, Jackson O'Byrne, Sharon
spellingShingle	Rutgeerts, Paul J Fedorak, Richard N Hommes, Daan W Sturm, Andreas Baumgart, Daniel C Bressler, Brian Schreiber, Stefan Mansfield, John C Williams, Marna Tang, Meina Visich, Jennifer Wei, Xiaohui Keir, Mary Luca, Diana Danilenko, Dimitri Egen, Jackson O'Byrne, Sharon A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
author_facet	Rutgeerts, Paul J Fedorak, Richard N Hommes, Daan W Sturm, Andreas Baumgart, Daniel C Bressler, Brian Schreiber, Stefan Mansfield, John C Williams, Marna Tang, Meina Visich, Jennifer Wei, Xiaohui Keir, Mary Luca, Diana Danilenko, Dimitri Egen, Jackson O'Byrne, Sharon
author_sort	Rutgeerts, Paul J
title	A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
title_short	A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
title_full	A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
title_fullStr	A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
title_full_unstemmed	A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
title_sort	randomised phase i study of etrolizumab (rhumab β7) in moderate to severe ulcerative colitis
description
publisher	BMJ Group
publishDate	2013
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711369/
_version_	1611994817673297920

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

Similar Items